A great range of immunomodulatory molecules is available in RA treatment from steroids to biologic and nonbiologic disease modifying antirheumatic drugs, of which the most used are, respectively, TNF-α blockers and methotrexate. The gene discussed is TNF; the disease is rheumatoid arthritis.